-
1.发明公开COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 失效组成和丙型肝炎的方法对病毒病的复合材料的处理。
公开(公告)号：EP0662157A1
公开(公告)日：1995-07-12
申请号：EP93919644.0
申请日：1993-09-10
申请人： MOCHIDA PHARMACEUTICAL CO., LTD. , JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE , ISIS PHARMACEUTICALS, INC.
发明人： ANDERSON, Kevin, P. , HANECAK, Ronnie, C. , HOSHIKO, Kazuya , NOZAKI, Chikateru , NISHIHARA, Tsukasa , NAKATAKE, Hiroshi , HAMADA, Fukusaburo , ETO, Tatsuo , FURUKAWA, Shinichi
CPC分类号： C12N15/1131 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/33 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707
摘要： Antisense oligonucleotides are provided which are complementary to at least a portion of HCV RNA and specifically hybridizable therewith. These oligonucleotides can be administered to inhibit the replication of Hepatitis C virus in vivo or in vitro and to treat Hepatitis C virus-associated disease. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus.
-
2.发明授权COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 有权组合物和方法用于治疗丙型肝炎病毒相关疾病的治疗
公开(公告)号：EP1035870B1
公开(公告)日：2005-02-23
申请号：EP98960818.7
申请日：1998-12-08
CPC分类号： C12N15/1131 , A61K38/00 , C07K14/005 , C12N2310/315 , C12N2310/318 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/33 , C12N2310/334 , C12N2310/341 , C12N2310/346 , C12N2770/24222 , C12Q1/707 , C12N2310/3525 , C12N2310/3527 , C12N2310/3521
摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
-
3.发明公开COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 有权组合物和方法用于治疗丙型肝炎病毒相关疾病的治疗
公开(公告)号：EP1035870A1
公开(公告)日：2000-09-20
申请号：EP98960818.7
申请日：1998-12-08
CPC分类号： C12N15/1131 , A61K38/00 , C07K14/005 , C12N2310/315 , C12N2310/318 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/33 , C12N2310/334 , C12N2310/341 , C12N2310/346 , C12N2770/24222 , C12Q1/707 , C12N2310/3525 , C12N2310/3527 , C12N2310/3521
摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
-
公开(公告)号：EP0673435A1
公开(公告)日：1995-09-27
申请号：EP92919266.0
申请日：1992-08-21
发明人： ECKER, David, J. , WYATT, Jacqueline , BRUICE, Thomas, W. , ANDERSON, Kevin , HANECAK, Ronnie, C. , VICKERS, Timothy , DAVIS, Peter
CPC分类号： G01N33/5308 , C12Q1/6811 , C12Q1/6827 , C12Q1/6853 , C12Q1/686 , C12Q1/6869 , C12Q1/70 , C12Q2537/143
摘要： Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled subunits are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.
-
公开(公告)号：EP0672193A1
公开(公告)日：1995-09-20
申请号：EP93922788.0
申请日：1993-09-29
发明人： HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BENNETT, C., Frank , CHIANG, Ming-Yi , BROWN-DRIVER, Vickie, L. , ECKER, David, J. , VICKERS, Timothy, A. , WYATT, Jacqueline, R. , IMBACH, Jean, Louis Impasse des Lucques
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/115 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.
-
6.发明授权USE OF OLIGONUCLEOTIDES HAVING A CONSERVED G 4 CORE SEQUENCE FOR THE PREPARATION OF A MEDICAMENT 失效具有保持G4 KEY序列的寡核苷酸用于生产药物的应用
公开(公告)号：EP0672193B1
公开(公告)日：2002-08-14
申请号：EP93922788.0
申请日：1993-09-29
发明人： HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BENNETT, C., Frank , CHIANG, Ming-Yi , BROWN-DRIVER, Vickie, L. , ECKER, David, J. , VICKERS, Timothy, A. , WYATT, Jacqueline, R. , IMBACH, Jean, Louis Impasse des Lucques
CPC分类号： A61K31/70 , A61K38/00 , C07H21/00 , C12N15/1133 , C12N15/1137 , C12N15/115 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12Q1/701 , C12Y207/07049 , C12Y301/01004 , C12N2310/3521
摘要： Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.
-
7.发明授权COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 失效组合物和方法丙型肝炎病毒与相关的疾病
公开(公告)号：EP0662157B1
公开(公告)日：2001-06-20
申请号：EP93919644.0
申请日：1993-09-10
发明人： ANDERSON, Kevin, P. , HANECAK, Ronnie, C. , HOSHIKO, Kazuya , NOZAKI, Chikateru , NISHIHARA, Tsukasa , NAKATAKE, Hiroshi , HAMADA, Fukusaburo , ETO, Tatsuo , FURUKAWA, Shinichi
IPC分类号： C12Q1/70 , C12N15/11 , C07H21/00 , G01N33/576
CPC分类号： C12N15/1131 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/33 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707
摘要： Antisense oligonucleotides are provided which are complementary to at least a portion of HCV RNA and specifically hybridizable therewith. These oligonucleotides can be administered to inhibit the replication of Hepatitis C virus in vivo or in vitro and to treat Hepatitis C virus-associated disease. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus.
-
公开(公告)号：EP0692930A1
公开(公告)日：1996-01-24
申请号：EP94910879.0
申请日：1994-03-07
发明人： DRAPER, Kenneth, G. , CROOKE, Stanley, T. , MIRABELLI, Christopher, K. , ECKER, David, J. , HANECAK, Ronnie, C. , ANDERSON, Kevin, P. , BROWN-DRIVER, Vickie, L. , WYATT, Jacqueline, R.
CPC分类号： C12N15/1133 , A61K31/70 , A61K38/00 , C07H21/00 , C07K14/005 , C12N15/1137 , C12N15/117 , C12N2310/151 , C12N2310/18 , C12N2310/3125 , C12N2310/315 , C12N2310/321 , C12N2310/33 , C12N2310/346 , C12N2310/3517 , C12N2310/3521 , C12N2710/16622 , C12Q1/701 , C12Y207/07049 , C12Y301/01004
摘要： Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.024 秒)
